Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company's wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARRY
  • CUSIP: 04269X10
Key Metrics:
  • Previous Close: $6.59
  • 50 Day Moving Average: $3.76
  • 200 Day Moving Average: $3.45
  • 52-Week Range: $2.38 - $7.27
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.96
  • P/E Growth: -0.90
  • Market Cap: $910.74M
  • Outstanding Shares: 145,022,000
  • Beta: 2.11
Profitability:
  • Net Margins: -67.33%
  • Return on Equity: -568.67%
  • Return on Assets: -49.40%
Debt:
  • Debt-to-Equity Ratio: -3.00%
  • Current Ratio: 2.96%
  • Quick Ratio: 2.96%
Additional Links:
Companies Related to Array BioPharma:

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (43.43% upside)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016JPMorgan Chase & Co.Reiterated RatingOverweight$6.00 -> $8.00View Rating Details
9/27/2016Jefferies GroupBoost Price TargetBuy -> Buy$7.00 -> $8.00View Rating Details
9/26/2016Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details
9/26/2016Leerink SwannBoost Price TargetOverweight -> Outperform$6.00 -> $9.00View Rating Details
9/26/2016Piper Jaffray Cos.Boost Price TargetOverweight$7.00 -> $10.00View Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$7.00 -> $8.00View Rating Details
6/2/2016SunTrust Banks Inc.Initiated CoverageBuy$7.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Array BioPharma (NASDAQ:ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/4/2016Q416($0.14)($0.16)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.18)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.63 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.18)($0.15)($0.16)
Q2 20163($0.18)($0.14)($0.16)
Q4 20163($0.27)$0.09($0.13)
Q1 20172($0.22)($0.21)($0.22)
Q2 20172($0.27)($0.22)($0.25)
Q3 20172($0.26)($0.24)($0.25)
Q4 20172($0.34)($0.19)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 85.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Array BioPharma (NASDAQ:ARRY)
DateHeadline
News IconArray BioPharma Inc. (NASDAQ:ARRY) Insider Trading Report - Newburgh Press (NASDAQ:ARRY)
newburghpress.com - September 29 at 8:23 AM
prnewswire.com logoArray BioPharma Announces Pricing of Public Offering of Common Stock - PR Newswire (press release) (NASDAQ:ARRY)
www.prnewswire.com - September 29 at 8:23 AM
News IconOverbuying Alert on: Array Biopharma Inc (NASDAQ:ARRY) - Post Registrar (NASDAQ:ARRY)
postregistrar.com - September 29 at 8:23 AM
investopedia.com logoArray BioPharma Reports Positive Results (ARRY) - Investopedia (NASDAQ:ARRY)
www.investopedia.com - September 29 at 8:23 AM
smarteranalyst.com logoJP Morgan Hikes Price Target on Array BioPharma Inc (ARRY) Following Positive COLUMBUS Phase 3 Results - Smarter Analyst (NASDAQ:ARRY)
www.smarteranalyst.com - September 28 at 3:32 PM
streetinsider.com logoArray Biopharma (ARRY) Prices 18.4M Share Stock Offering for Proceeds of ~$115M - StreetInsider.com (NASDAQ:ARRY)
www.streetinsider.com - September 28 at 8:22 AM
News IconAnalysts Valuations For Two Stocks: Real Gds Solar (SWX:RGSE), Array Biopharma Inc (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:ARRY)
voiceregistrar.com - September 28 at 8:22 AM
publicnow.com logoArray BioPharma Announces Pricing of Public Offering of Common Stock (NASDAQ:ARRY)
www.publicnow.com - September 28 at 8:22 AM
finance.yahoo.com logo2:40 am Array Biopharma prices offering of 18.4 mln shares of its common stock at $6.25 per share (NASDAQ:ARRY)
finance.yahoo.com - September 28 at 8:22 AM
seekingalpha.com logoArray BioPharma prices upsized equity offering at $6.25 (NASDAQ:ARRY)
seekingalpha.com - September 28 at 7:39 AM
seekingalpha.com logoArray BioPharma launches $100M equity offering; shares off 4% after hours (NASDAQ:ARRY)
seekingalpha.com - September 27 at 6:45 PM
News IconBiotech Stocks Worth Chasing: PDL BioPharma, Inc. (PDLI), Array BioPharma Inc. (ARRY) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 27 at 3:34 PM
News IconBiotech Stocks Worth Chasing: PDL BioPharma, Inc. (PDLI), Array BioPharma Inc. (ARRY) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 27 at 3:34 PM
schaeffersresearch.com logoAnalyst Upgrades: Twitter Inc, Array Biopharma Inc, and Eli Lilly and Co - Schaeffers Research (blog) (NASDAQ:ARRY)
www.schaeffersresearch.com - September 27 at 3:34 PM
schaeffersresearch.com logoAnalyst Upgrades: Twitter Inc, Array Biopharma Inc, and Eli Lilly and Co - Schaeffers Research (blog) (NASDAQ:ARRY)
www.schaeffersresearch.com - September 27 at 3:34 PM
investorplace.com logo3 Stocks to Watch Tuesday: Kite Pharma Inc (KITE), Array Biopharma Inc (ARRY) and Mylan NV (MYL) - Investorplace.com (NASDAQ:ARRY)
investorplace.com - September 27 at 3:34 PM
investorplace.com logo3 Stocks to Watch Tuesday: Kite Pharma Inc (KITE), Array Biopharma Inc (ARRY) and Mylan NV (MYL) - Investorplace.com (NASDAQ:ARRY)
investorplace.com - September 27 at 3:34 PM
investorplace.com logoArray Biopharma Inc (ARRY) Surges 60% as Shorts Get Squeezed - Investorplace.com (NASDAQ:ARRY)
investorplace.com - September 27 at 8:07 AM
News IconTrading the Biotech News: BioTime, Inc. (NYSEMKT:BTX), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:ARRY)
voiceregistrar.com - September 26 at 3:36 PM
smarteranalyst.com logoHealthcare Analysts Change Price Targets on Array Biopharma Inc (ARRY) and Incyte Corporation (INCY) - Smarter Analyst (NASDAQ:ARRY)
www.smarteranalyst.com - September 26 at 3:36 PM
insidermonkey.com logoWhy Investors Are Buzzing About Yum, Twitter, GM, RetailMeNot, and Array Biopharma Today (NASDAQ:ARRY)
www.insidermonkey.com - September 26 at 3:36 PM
fool.com logoWhy Array BioPharma Inc Is Surging Today (NASDAQ:ARRY)
www.fool.com - September 26 at 12:37 PM
publicnow.com logoArray BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint (NASDAQ:ARRY)
www.publicnow.com - September 26 at 8:16 AM
News IconBiotech stocks for your portfolio: Array BioPharma Inc. (ARRY), Celldex Therapeutics, Inc. (CLDX) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 23 at 3:59 PM
News IconBiotech Stocks To Put On Your Watch List: PDL BioPharma, Inc. (NASDAQ:PDLI), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:ARRY)
voiceregistrar.com - September 22 at 3:34 PM
News IconBiotech stocks for your portfolio: Array BioPharma (ARRY), Alexion Pharmaceuticals (ALXN) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 22 at 3:34 PM
News IconAnalysts Valuations For Two Stocks: Navistar International Corp (NYSE:NAV), Array Biopharma Inc (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:ARRY)
voiceregistrar.com - September 22 at 3:34 PM
News IconArray BioPharma Inc.'s (ARRY) - Cosumnes Connection (subscription) (NASDAQ:ARRY)
www.crcconnection.com - September 21 at 8:40 AM
News IconAdvancing Preclinical Autoimmune Studies & Accelerated FDA Approvals Producing Rewards in Biotech Sector (NASDAQ:ARRY)
ih.advfn.com - September 20 at 3:34 PM
News IconFirst Week of ARRY November 18th Options Trading (NASDAQ:ARRY)
www.stockoptionschannel.com - September 20 at 3:34 PM
News IconScorching Hot Biotech Stocks Tape: Array BioPharma Inc. (ARRY ... - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 20 at 9:31 AM
News IconArray BioPharma Inc. (NASDAQ:ARRY) Upgrades/Downgrades Update - Newburgh Press (NASDAQ:ARRY)
newburghpress.com - September 20 at 9:31 AM
capitalcube.com logoArray BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : September 20, 2016 (NASDAQ:ARRY)
www.capitalcube.com - September 20 at 9:31 AM
News IconHC Stocks Midpoint! Brookdale Senior Living, Inc. (BKD), Array Biopharma Inc (NASDAQ:ARRY) - share market updates (press release) (NASDAQ:ARRY)
sharemarketupdates.com - September 19 at 8:23 AM
247wallst.com logo10 Analyst Stock Picks Under $10 for Massive Upside - 24/7 Wall St. (NASDAQ:ARRY)
247wallst.com - September 18 at 3:33 PM
4-traders.com logoArray BioPharma : Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma (NASDAQ:ARRY)
www.4-traders.com - September 17 at 3:35 PM
News IconBiotech news that matter for investors: ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:ARRY)
voiceregistrar.com - September 17 at 8:23 AM
News Icon2 Sizzling Hot Biotechnology Stocks: Array BioPharma Inc. (ARRY), ZIOPHARM Oncology, Inc. (ZIOP) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 16 at 3:34 PM
investopedia.com logoArray Secures SPA Agreement With FDA for Colorectal Cancer Trial ... - Investopedia (NASDAQ:ARRY)
www.investopedia.com - September 15 at 3:33 PM
4-traders.com logoARRAY BIOPHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ARRY)
www.4-traders.com - September 15 at 12:29 PM
investopedia.com logoArray Secures SPA Agreement With FDA for Colorectal Cancer Trial (ARRY) (NASDAQ:ARRY)
www.investopedia.com - September 14 at 8:49 PM
News IconHC Stocks in Hub= Array Biopharma Inc (ARRY), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release) (NASDAQ:ARRY)
sharemarketupdates.com - September 14 at 3:36 PM
finance.yahoo.com logoArray BioPharma Announces Phase 3 BEACON CRC SPA Agreement with FDA (NASDAQ:ARRY)
finance.yahoo.com - September 14 at 7:42 AM
biz.yahoo.com logoARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ARRY)
biz.yahoo.com - September 14 at 7:42 AM
investopedia.com logoWhy Array Biopharma May Become a Winner (ARRY) - Investopedia (NASDAQ:ARRY)
www.investopedia.com - September 13 at 3:35 PM
investopedia.com logoWhy Array Biopharma May Become a Winner (ARRY) (NASDAQ:ARRY)
www.investopedia.com - September 12 at 3:34 PM
investopedia.com logoHow To Approach Momentum Trading Like A Pro (NASDAQ:ARRY)
www.investopedia.com - September 12 at 8:21 AM
capitalcube.com logoArray BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : September 9, 2016 (NASDAQ:ARRY)
www.capitalcube.com - September 9 at 8:23 AM
News IconTwo Biotech Stocks Are Just So Hot Right Now: Array BioPharma (ARRY), Intrexon (XON) - The Independent Republic (NASDAQ:ARRY)
theindependentrepublic.com - September 7 at 8:43 PM
seekingalpha.com logoArray Plays The Cardiovascular Card - Seeking Alpha (NASDAQ:ARRY)
seekingalpha.com - September 7 at 12:38 PM

Social

Array BioPharma (NASDAQ:ARRY) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff